Both works support previous reports suggesting that the relationship between elevated VEGF levels, improved cognitive function, and fewer anatomical and physiological alterations could be explained by the beneficial effect of VEGF on the hippocampus [114,115]; however, the combination of VEGF levels, the 3 classical CSF biomarkers of AD (Aβ1-42, T-tau, and p-tau), and another marker (heart-type fatty acid binding protein) displayed a sensitivity of 82.61% and specificity of 85.71% to distinguish between AD and controls [125]. The gene discussed is VEGFA; the disease is Alzheimer disease.